Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03364309
Recruitment Status : Active, not recruiting
First Posted : December 6, 2017
Last Update Posted : August 29, 2019
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Drug: Ixekizumab Drug: Placebo Phase 3

Detailed Description:
Study I1F-MC-RHBH is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study examining the effect of 2 dose regimens of ixekizumab versus placebo in participants with moderate-to-severe plaque psoriasis (Ps) during an induction dosing period with dosing for 12 weeks and the primary endpoint measured at 12 weeks, followed by a randomized, 48-week maintenance dosing period. During the maintenance dosing period, the study will evaluate the maintenance of response/remission, as well as relapse or rebound following treatment withdrawal, and response to retreatment following relapse.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 438 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
Actual Study Start Date : April 26, 2018
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Ixekizumab

Arm Intervention/treatment
Experimental: Ixekizumab Dose Schedule 1
Ixekizumab given subcutaneously (SC).
Drug: Ixekizumab
Administered SC
Other Name: LY2439821

Experimental: Ixekizumab Dose Schedule 2
Ixekizumab given SC. Placebo given SC to maintain blind.
Drug: Ixekizumab
Administered SC
Other Name: LY2439821

Drug: Placebo
Administered SC

Placebo Comparator: Placebo
Placebo given SC
Drug: Placebo
Administered SC




Primary Outcome Measures :
  1. Proportion of Participants with a static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement from Baseline [ Time Frame: Week 12 ]
    Proportion of Participants with a sPGA score of clear (0) or minimal (1) with at least a 2 point improvement from baseline

  2. Proportion of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75) from Baseline [ Time Frame: Week 12 ]
    Proportion of participants achieving a ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) from baseline


Secondary Outcome Measures :
  1. Proportion of Participants Achieving a static Physician Global Assessment (sPGA) Score of Clear (0) (Remission) [ Time Frame: Week 12 ]
    Proportion of participants achieving a sPGA score of clear (0) (remission)

  2. Proportion of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) from Baseline [ Time Frame: Week 12 ]
    Proportion of participants achieving a ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) from baseline

  3. Proportion of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) from Baseline [ Time Frame: Week 12 ]
    Proportion of participants achieving a 100% improvement in Psoriasis Area and Severity Index (PASI 100) from baseline

  4. Proportion of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction from Baseline for Participants who had Baseline Itch NRS ≥4 [ Time Frame: Week 12 ]
    Proportion of participants achieving an Itch NRS ≥4 point reduction from baseline for participants who had baseline Itch NRS ≥4

  5. Change from Baseline in Dermatology Life Quality Index (DLQI) Total Score [ Time Frame: Baseline, Week 12 ]
    Change from baseline in DLQI total score

  6. Change from Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants with Baseline Fingernail Involvement [ Time Frame: Baseline, Week 12 ]
    Change from baseline in NAPSI score in participants with baseline fingernail involvement

  7. Change from Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis [ Time Frame: Baseline, Week 12 ]
    Change from baseline in percent of BSA involvement of psoriasis

  8. Change from Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants with Baseline Scalp Involvement [ Time Frame: Baseline, Week 12 ]
    Change from baseline in PSSI score in participants with baseline scalp involvement

  9. Change from Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score [ Time Frame: Baseline, Week 12 ]
    Change from baseline in medical outcomes study SF-36 PCS score

  10. Change from Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score [ Time Frame: Baseline, Week 12 ]
    Change from baseline in medical outcomes study SF-36 MCS score

  11. Change from Baseline on Patient Global Assessment of Disease Severity (Scale is from 0 [Clear] = no Ps to 5 [Severe]) [ Time Frame: Baseline, Week 12 ]
    Change from baseline on Patient Global Assessment of Disease Severity (scale is from 0 [clear] = no Ps to 5 [severe])

  12. Change from Baseline in Palmoplantar PASI (PPASI) in Participants with Baseline Palmoplantar Involvement [ Time Frame: Baseline, Week 12 ]
    Change from baseline in PPASI in participants with baseline palmoplantar involvement

  13. Change from Baseline on the Joint Pain Visual Analog Scale (VAS) [ Time Frame: Baseline, Week 12 ]
    Change from baseline on the joint pain VAS

  14. Percentage of Participants with Anti-Ixekizumab Antibodies [ Time Frame: Baseline through Week 12 ]
    Percentage of participants with anti-ixekizumab antibodies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Present with chronic plaque Ps based on a confirmed diagnosis of chronic Ps vulgaris for at least 6 months prior to baseline.
  • Have ≥10% BSA involvement at screening and baseline.
  • Have both an sPGA score ≥3 and PASI score ≥12 at screening and baseline.
  • Are candidates for phototherapy and/or systemic therapy.

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline.
  • Drug-induced psoriasis.
  • Ongoing use of prohibited treatments.
  • Have previously completed or withdrawn from this study, or have previously exposed to ixekizumab or any other biologic drug directly targeting interleukin-17 (IL-17) (such as secukinumab) or the IL-17 receptor.
  • Have concurrent or recent use of any biologic agent within washout periods or <5 half-lives prior to baseline, whichever is longer.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364309


Locations
Show Show 17 study locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT03364309    
Other Study ID Numbers: 14438
I1F-MC-RHBH ( Other Identifier: Eli Lilly and Company )
First Posted: December 6, 2017    Key Record Dates
Last Update Posted: August 29, 2019
Last Verified: August 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Eli Lilly and Company:
plaque psoriasis
ixekizumab
skin condition
skin disease
itching
psoriasis vulgaris
immune-mediated systemic disease
skin lesions
scaly patches
papules
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Ixekizumab
Dermatologic Agents